$1.20
7.14% today
Nasdaq, Apr 29, 06:49 pm CET
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Immunic, Inc. Stock price

$1.12
-0.08 6.67% 1M
-0.22 16.42% 6M
+0.12 12.00% YTD
-0.11 8.94% 1Y
-6.17 84.64% 3Y
-7.82 87.47% 5Y
-1,108.08 99.90% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+0.01 0.90%
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Key metrics

Market capitalization $107.32m
Enterprise Value $72.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.48
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-98.05m
Free Cash Flow (TTM) Free Cash Flow $-85.03m
Cash position $35.67m
EPS (TTM) EPS $-1.04
P/E forward negative
Short interest 2.20%
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Immunic, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Immunic, Inc. forecast:

Buy
100%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
18% 18%
-
-0.13 -0.13
18% 18%
-
- Selling and Administrative Expenses 18 18
12% 12%
-
- Research and Development Expense 80 80
4% 4%
-
-98 -98
1% 1%
-
- Depreciation and Amortization 0.13 0.13
18% 18%
-
EBIT (Operating Income) EBIT -98 -98
1% 1%
-
Net Profit -101 -101
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Positive
Seeking Alpha
one day ago
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammator...
Neutral
PRNewsWire
19 days ago
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90...
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 91
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today